clinical trials
3 articles tagged with ‘clinical trials’

Eloralintide: The Amylin Agonist in Phase 3, and Why It Is the Hardest Compound to Verify
Eloralintide inverts the usual trade-off: a randomised 48-week trial in the Lancet, nine phase 3 studies recruiting, and almost no independent analytical infrastructure. Why amylin is not an incretin, and what a certificate for a compound still in development can prove.

Reading Peptide Trial Results: Why Two Trials Give Different Numbers
One trial, one dataset, two correct headline figures. What an estimand is, why a percentage taken from one trial and compared with a percentage from another is not an estimate of anything, and a worked example of how far off that comparison can be.

What the Human Evidence Actually Shows: A Peptide Evidence Map
Thymosin beta-4 has been through a Phase 3 trial. It was an eye drop, in a corneal disease, and it missed. A five-tier map of where each peptide's evidence actually sits, and why a registered trial that never published is weaker than no trial at all.
